Inozyme Pharma to Present at the BofA Securities 2021 Virtual Healthcare Conference
06 mai 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced...
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency
29 avr. 2021 07h30 HE
|
Inozyme Pharma Inc.
- Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse...
Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences
28 avr. 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization...
Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
14 avr. 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today...
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting
08 avr. 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of...
Inozyme Pharma Expands its Scientific Advisory Board
01 avr. 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization,...
Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights
25 mars 2021 06h00 HE
|
Inozyme Pharma Inc.
– Received Orphan Drug Designation by the U.S. Food and Drug Administration for INZ-701 for treatment of ABCC6 deficiency – – Expect to initiate Phase 1/2 trials of INZ-701 for ENPP1 deficiency in...
The Balancing Act® on Lifetime to Feature ENPP1 Deficiency
11 mars 2021 07h30 HE
|
Inozyme Pharma Inc.
BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization,...
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer
04 févr. 2021 06h00 HE
|
Inozyme Pharma Inc.
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
04 janv. 2021 06h00 HE
|
Inozyme Pharma Inc.
– U.S. Food and Drug Administration cleared Investigational New Drug Application – – United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application – –...